四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.
四 環 醫 藥 控 股 集 團 有 限 公 司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

POSITIVE PROFIT ALERT

This announcement is issued by Sihuan Pharmaceutical Holdings Group Ltd. (the "**Company**" or "**Sihuan Pharmaceutical**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong).

The board of directors of the Company (the "**Board**") would like to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Company for the six months ended 30 June 2026 (the "**Period**") and the information currently available to the Board, the Group is expected to record a revenue of not less than RMB1,140 million for the Period, which is roughly the same for the same period of last year and a net profit of not less than RMB210 million for the Period, which represents an increase of not less than 217.2% compared to that for the same period of last year.

The factors affecting the financial results of the Group for the Period primarily include the following:

1. The medical aesthetics business maintained steady development. The medical aesthetics business sector of the Group continued to benefit from the stable growth of its core product, Letybo® (botulinum toxin), as well as the continuous increase in sales volume of regenerative medical aesthetics products (including PLLA and PCL) and functional medical aesthetics products, driving the related business revenue to maintain growth. The medical aesthetics business recorded a revenue of no less than RMB680 million for the Period, with an increase of no less than 16.1% compared to that for the same period of last year, and contributed a segment profit of not less than RMB320 million for the Period, continuing to be an important source of profit for the Group.

2. The commercialization process of the innovative drug business continued to advance. The commercialization and internationalization of multiple approved products are progressing well, with consolidated revenue achieving significant growth and net loss being substantially reduced.

3. There was a significant increase in share of profits of an associate. The Group has recognized share of profits of not less than RMB110 million for the Period mainly due to a successful IPO and listing of investment projects invested by the associate.

4. Optimizing asset structure brings benefits. Faced with the impact of national policies such as volume-based procurement on the generic drug business, the Group has continued to promote the optimization of the generic drug business and asset integration. The divestment of related assets generated gains of not less than RMB140 million for the Period, further enhancing the overall profitability and resource allocation efficiency of the Group.

With the two core sectors such as medical aesthetics business and innovative drugs business entering the harvest period and maintaining high-speed growth, the overall performance structure of the Group continues to optimize, and the profitability steadily improves, marking the Group's official entry into a new stage of high-quality development. The Board believes that the Group has a clear strategic path, a complete product lineup, and an accelerated internationalization process. In the future, the Group will continue to adhere to an innovation driven and differentiated layout, and be committed to creating long-term sustainable returns for shareholders and investors.

The Board would like to remind the Shareholders and potential investors that the information contained in this announcement has not been reviewed or audited by the independent auditor or the audit committee of the Company and may be subject to adjustments. The actual results of the Company for the Period may differ from the information contained in this announcement. Detailed financial information of the Company for the Period will be disclosed in the interim results announcement of the Company, which is expected to be published before the end of August 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 27 July 2026

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.